Cargando…
Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs
The current standard of care for paroxysmal nocturnal hemoglobinuria (PNH) are the C5 inhibitors eculizumab and ravulizumab, both monoclonal antibodies designed to target the complement protein C5, thereby preventing its cleavage and the formation of the terminal attack complex. C5 inhibitors have y...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410676/ https://www.ncbi.nlm.nih.gov/pubmed/33356783 http://dx.doi.org/10.18553/jmcp.2020.26.12-b.s14 |